nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

05.01.2024 | Head and Neck

Overall survival, disease-free survival and quality of life in patients affected by HPV mediated p16+ oropharyngeal squamous cell carcinoma treated with upfront trans-oral robotic surgery vs radiotherapy or chemoradiotherapy

verfasst von: Giacomo Fiacchini, Miriana Picariello, Iacopo Dallan, Domenico Tricò, Augusto Pietro Casani, Federica Amato, Fabiola Paiar, Stefano Ursino, Stefano Berrettini, Luca Bruschini

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Treatment de-intensification for p16 + oropharyngeal squamous cell carcinoma (OPSCC) is an area of active research to reduce the side effects and improve patients’ quality of life (QoL). In this paper we evaluated the Overall Survival (OS), the Disease-Free Survival (DFS) and the QoL of patients affected by p16 + OPSCC according to their prognostic stage group (PSG) and different treatments.

Methods

Patients were selected retrospectively through our Electronic Tumor Board Database according to prespecified inclusion criteria. Basic data of eligible patients were recorded and analyzed. Then, OS and DFS were evaluated according to the PSG and the treatments performed. Patients alive completed three questionnaires: the QoL Questionnaire Core 30 (QLQ-C30), the QoL Questionnaire Head & Neck 43 (QLQ-HN43) and the MD Anderson Dysphagia Inventory (MDADI) questionnaire.

Results

Sixty-one patients were included in this study. Eight patients died from the disease and the remaining 53 patients completed the 3 questionnaires. Fifteen (25%) patients were treated with upfront surgery, 6 (10%) patients with definitive radiotherapy and 40 (65%) patients with concomitant chemoradiotherapy. Comparing the DFS and the OS of PSG I patients by the different treatments performed, no statistically significant difference was identified. Patients treated with upfront surgery showed better outcomes in some aspects of their QoL.

Conclusion

For p16 + OPSCC PSG I patients, upfront surgery can be considered a valid alternative to radiotherapy or chemoradiotherapy while maintaining a comparable DFS and OS and giving patients better results in terms of specific aspects of their QoL.

Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. JNCI J Natl Cancer Inst 100:261–269. https://doi.org/10.1093/jnci/djn011CrossRefPubMed

Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35. https://doi.org/10.1056/NEJMoa0912217CrossRefPubMedPubMedCentral

Pfister DG, Fury MG (2014) New chapter in our understanding of human papillomavirus-related head and neck cancer. JCO 32:3349–3352. https://doi.org/10.1200/JCO.2014.56.5754CrossRef

Mehanna H, Robinson M, Hartley A et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. The Lancet 393:51–60. https://doi.org/10.1016/S0140-6736(18)32752-1CrossRef

Swisher-McClure S, Lukens JN, Aggarwal C et al (2020) A phase 2 trial of alternative volumes of oropharyngeal irradiation for de-intensification (AVOID): omission of the resected primary tumor bed after transoral robotic surgery for human papilloma virus-related squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 106:725–732. https://doi.org/10.1016/j.ijrobp.2019.11.021CrossRefPubMed

Yom SS, Torres-Saavedra P, Caudell JJ et al (2021) Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). JCO 39:956–965. https://doi.org/10.1200/JCO.20.03128CrossRef

Ma DJ, Price KA, Moore EJ et al (2019) Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma. JCO 37:1909–1918. https://doi.org/10.1200/JCO.19.00463CrossRef

Ferris RL, Flamand Y, Weinstein GS et al (2022) Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311). JCO 40:138–149. https://doi.org/10.1200/JCO.21.01752CrossRef

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR et al (2017) AJCC cancer staging manual, 8th edn. Springer International Publishing: American Joint Commission on Cancer

10.

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. https://doi.org/10.1093/jnci/85.5.365CrossRefPubMed

11.

Bjordal K, de Graeff A, Fayers PM et al (2000) A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC quality of life group. Eur J Cancer 36:1796–1807. https://doi.org/10.1016/s0959-8049(00)00186-6CrossRefPubMed

12.

Singer S, Amdal CD, Hammerlid E et al (2019) International validation of the revised European organisation for research and treatment of cancer head and neck cancer module, the EORTC QLQ-HN43: phase IV. Head Neck 41:1725–1737. https://doi.org/10.1002/hed.25609CrossRefPubMed

13.

Schindler A, Borghi E, Tiddia C et al (2008) Adaptation and validation of the Italian MD Anderson dysphagia inventory (MDADI). Rev Laryngol Otol Rhinol (Bord) 129:97–100PubMed

14.

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels

15.

Dallan I, Cristofani-Mencacci L, Seccia V et al (2019) Transoral robotic tongue base reduction and supraglottoplasty combined with maxillomandibular advancement: a new option for selected sleep apnea patients? Preliminary report. Eur Arch Otorhinolaryngol 276:3543–3548. https://doi.org/10.1007/s00405-019-05671-7CrossRefPubMed

16.

Fiacchini G, Vianini M, Dallan I, Bruschini L (2020) Is the Da Vinci Xi system a real improvement for oncologic transoral robotic surgery? A systematic review of the literature. J Robot Surg. https://doi.org/10.1007/s11701-020-01132-0CrossRefPubMed

17.

Hegde JV, Shaverdian N, Daly ME et al (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: findings from a phase 2 trial. Cancer 124:521–529. https://doi.org/10.1002/cncr.30954CrossRefPubMed

18.

Nichols AC, Lang P, Prisman E et al (2020) Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial. BMC Cancer 20:125. https://doi.org/10.1186/s12885-020-6607-zCrossRefPubMedPubMedCentral

19.

Scott SI, Kathrine Ø, Madsen A, Rubek N et al (2021) Long-term quality of life & functional outcomes after treatment of oropharyngeal cancer. Cancer Med 10:483–495. https://doi.org/10.1002/cam4.3599CrossRefPubMed

20.

Haughey BH, Hinni ML, Salassa JR et al (2011) Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 33:1683–1694. https://doi.org/10.1002/hed.21669CrossRefPubMed

21.

Moore EJ, Hinni ML (2013) Critical review: transoral laser microsurgery and robotic-assisted surgery for oropharynx cancer including human papillomavirus-related cancer. Int J Radiat Oncol Biol Phys 85:1163–1167. https://doi.org/10.1016/j.ijrobp.2012.08.033CrossRefPubMed

22.

O’Hara J, Cosway B, Muirhead C et al (2015) Transoral laser microsurgery ± adjuvant therapy versus chemoradiotherapy for stage III and IVA oropharyngeal squamous cell carcinoma: preliminary comparison of early swallowing outcomes: comparison of early swallowing outcomes with transoral laser microsurgery. Head Neck 37:1488–1494. https://doi.org/10.1002/hed.23790CrossRefPubMed

23.

Owadally W, Hurt C, Timmins H et al (2015) PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer 15:602. https://doi.org/10.1186/s12885-015-1598-xCrossRefPubMedPubMedCentral

Titel: Overall survival, disease-free survival and quality of life in patients affected by HPV mediated p16+ oropharyngeal squamous cell carcinoma treated with upfront trans-oral robotic surgery vs radiotherapy or chemoradiotherapy
verfasst von: Giacomo Fiacchini
Miriana Picariello
Iacopo Dallan
Domenico Tricò
Augusto Pietro Casani
Federica Amato
Fabiola Paiar
Stefano Ursino
Stefano Berrettini
Luca Bruschini
Publikationsdatum: 05.01.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 4/2024
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-023-08432-9

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Overall survival, disease-free survival and quality of life in patients affected by HPV mediated p16+ oropharyngeal squamous cell carcinoma treated with upfront trans-oral robotic surgery vs radiotherapy or chemoradiotherapy